All lobbying filings

WHITMER & WORRALL, LLC

Lobbying for CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Coalition to promote lowering prescription drug prices.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Apr 21, 2025

Official filing document

Bills named in this filing 10

S 1041
Affordable Prescriptions for Patients Act
S 229
DTC Act of 2025
S 1097
Interagency Patent Coordination and Improvement Act of 2025
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
S 43
Skinny Labels, Big Savings Act
S 1040
Drug Competition Enhancement Act
S 1095
Stop STALLING Act
S 1032
Major Richard Star Act
HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 5573
Skinny Labels, Big Savings Act

Lobbying activity 3

Medicare/Medicaid

Issues related to prescription drug prices. S.1041 Affordable Prescriptions for Patients Act. Fair Accountability and Innovative Research Drug Pricing Act. S.229 Drug Price Transparency for Consumers Act.

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2023. S. 1097 Interagency Patent Coordination Act. Medication Affordability and Patent Integrity Act S. 1096 Preserve Access to Affordable Generics and Biosimilars Act Patent Eligibility Restoration Act PREVAIL Act S.5573 A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products. S.43 Skinny Labels, Big Savings Act S.1040 Drug Competition Enhancement Act

Pharmacy

Issues related to prescription drug pricing. Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. Ensuring Timely Access to Generics Act. S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.